| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0180c709e6805ab618dbfb1e4c4d240
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a830f4fe37ddf1fb0670fe60aae075fd |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 |
| filingDate |
2014-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_510f13814f2996bfa4fd055462559b26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eced6eccdfe4ffebee9bb207b6bd11c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0596cdc3125fc61c417b274ba4c778ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5a8cf08174b4d88187ddac1c9154a4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e452c5babfc2d4eef250594043bcad94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71af5d4a587534f28ca36dba6eb37bee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_083609328e9a619e4553bb99c165defc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4338cc099b9c2de22ed1481106cdda1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab2884f31e3c1b7413bbde6d19072949 |
| publicationDate |
2016-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2016101124-A |
| titleOfInvention |
Tuberculosis vaccine |
| abstract |
An object of the present invention is to provide a tuberculosis vaccine having a high ability to prevent infection and a long immunostimulatory effect. A recombinant BCG (BCG-PEST) was newly prepared by introducing a plasmid expressing a PEST-HSP70-MMP-II-PEST fusion protein using urease-deficient BCG as a host. The recombinant BCG of the present invention is superior in action and effect compared to conventional BCG-Tokyo strains and known recombinant BCG (BCG-DHTM, etc.) in in vitro tests and in vivo exposure tests for Mycobacterium tuberculosis. It was shown to be a tuberculosis vaccine with high infection-protective ability and a long immunostimulatory effect. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113499439-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113499439-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111979162-A |
| priorityDate |
2014-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |